Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.

Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Abstract Text:

Background: A major challenge in cancer chemotherapy has been developing safe and clinically efficacious chemotherapeutic agents. With its low toxicity profile, curcumin (diferuloylmethane), a naturally occurring flavinoid derived from the rhizome of Curcuma longa, has great promise. In vitro and in vivo preclinical studies have shown its inhibitory anticancer, antioxidant, anti-inflammatory, antiproliferative, and proapoptotic activities. The multiple mechanisms of the antitumor effect of curcumin putatively include down-regulating the expression of gene products such as nuclear factor-kappaB, growth suppression, inducing apoptosis, and modulating various signal transduction pathways and the expression of many oncogenes. The mechanisms underlying the antitumor activity of curcumin have not, however, been completely delineated. Methods: An oligonucleotide microarray chip was developed and used to profile microRNA (miRNA) expressions in pancreatic cells treated with curcumin. Transcripts with regulated expression patterns on the arrays were validated by real-time PCRs. Additionally, potential mRNA targets were analyzed bioinformatically and confirmed with flow cytometry experiments. Results: Curcumin alters miRNA expression in human pancreatic cells, up-regulating miRNA-22 and down-regulating miRNA-199a*, as confirmed by TaqMan real-time PCR. Upregulation of miRNA-22 expression by curcumin or by transfection with miRNA-22 mimetics in the PxBC-3 pancreatic cancer cell line suppressed expression of its target genes SP1 transcription factor (SP1) and estrogen receptor 1 (ESR1), while inhibiting miRNA-22 with antisense enhanced SP1 and ESR1 expression. Conclusions: These observations suggest that modulation of miRNA expression may be an important mechanism underlying the biological effects of curcumin. [Mol Cancer Ther 2008;7(3):464-73].

Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Molecular cancer therapeutics

VOLUME: 7

Page Numbers: 464-73

Journal Abbreviation: Mol. Cancer Ther.

ISSN: 1535-7163

DAY: 18

MONTH: Mar

YEAR: 2008

Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101132535

Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.

AFFILIATION: Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0455, Houston, TX 77030. rkurzroc@mdanderson.org.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Mol Cancer Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Curcumin diferuloylmethane alters the expression profiles of microRNAs in human pancreatic cancer cells Related Publications

• Beta1 integrin expression pattern in transitional urothelium does not allow for efficient stem cell enrichment as in other epithelia.
• Complete bladder duplication presenting as incontinence in an 11-year-old girl.
• Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.
• Cutaneous castleman's disease responds to anti interleukin-6 treatment.
• Development and validation of the fecal incontinence and constipation quality of life measure in children with spina bifida.
• Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials.
• How do we measure hypospadias outcomes?
• Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides.
• Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics.
• Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
• Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
• Non-surgical management of multicystic dysplastic kidney.
• Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies.
• Short stay pyeloplasty: variables affecting pain and length of stay.
• Studies in target-based treatment.
• The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
• [Vinca rosea in the treatment of hemoblastoses and similar clinical pictures.]